Theriva Biologics Announces Positive VIRAGE Phase 2b Results

Theriva Biologics ( (TOVX) ) has provided an announcement.

On May 7, 2025, Theriva Biologics announced positive results from the VIRAGE Phase 2b clinical trial for its lead product candidate VCN-01 in combination with standard-of-care chemotherapy for metastatic pancreatic ductal adenocarcinoma. The trial showed that patients receiving VCN-01 had a median overall survival of 10.8 months compared to 8.6 months for those on standard chemotherapy alone. The combination treatment also improved progression-free survival and duration of response, with the second dose of VCN-01 providing additional benefits. The safety profile of VCN-01 was consistent with previous trials, and adverse events were transient and reversible. These findings suggest that VCN-01 could become a significant therapeutic option for this challenging cancer, potentially influencing future industry partnerships and the design of a Phase 3 trial.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, particularly in areas with high unmet needs. The company’s lead product candidate, VCN-01, is an oncolytic adenovirus designed to selectively replicate within tumor cells and degrade the tumor stroma, enhancing the effectiveness of co-administered cancer therapies.

Average Trading Volume: 31,029

Technical Sentiment Signal: Sell

Current Market Cap: $3.78M

Learn more about TOVX stock on TipRanks’ Stock Analysis page.